Self-control and executive functioning are often treated as highly related psychological constructs. However, measures of each rarely correlate with one another. This reflects some combination of true separability between the constructs and measurement differences. Traditionally, executive functioning is objectively measured as performance on computer-controlled tasks in the laboratory, whereas self-control is subjectively measured with self-report scales of predispositions and behaviors in everyday life. Self-report measures tend to better predict outcomes that should be affected by individual differences in control. Our two studies show that the original version of Tangney, Baumeister, and Boone's brief self-control scale (consisting of four positive and nine negative items) strongly correlates with self-esteem, mental health, fluid intelligence, but only weakly with satisfaction with life and happiness. Four variants of the original scale were created by reverse-wording the 13 original items and recombining them to form, for example, versions with all positive or all negative items. As the proportion of items with positive valence increased: (1) the outcomes with strong correlations in the original scale weakened and the weak correlations strengthened and (2) the mean overall scores increased. Both studies replicated a common finding that the original scale yields two factors in an exploratory factor analysis. However, the second factor is generated by method differences, namely, having items with both positive and negative valence. The second factor is induced by the common practice of reverse-coding the items with negative valence and the faulty assumption that Likert scales are equal-interval scales with a neutral-point at midscale.

Download full-text PDF

Source
http://dx.doi.org/10.3758/s13428-023-02089-2DOI Listing

Publication Analysis

Top Keywords

positive negative
12
original scale
12
likert scales
8
self-report measures
8
measures self-control
8
executive functioning
8
negative items
8
items positive
8
second factor
8
negative valence
8

Similar Publications

Background: Pharmacoepidemiologic studies assessing drug effectiveness for Alzheimer's disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real-world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.

Method: We developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011-2013; mean age 75.

View Article and Find Full Text PDF

Background: Memory is influenced by epigenetic mechanisms that regulate gene expression. Histone acetyltransferases (HATs), and histone deacetylases (HDACs), are two competitive enzymes regulating histone acetylation. Histone acetylation is reduced in Alzheimer's disease (AD) brains, and evidence has shown a synergistic regulation of HDACs and HATs activities.

View Article and Find Full Text PDF

Background: SHIP1 is a phosphatidyl inositol phosphatase encoded by INPP5D, which has been identified as a risk gene for Alzheimer's disease (AD). SHIP1 is expressed in microglia, the resident macrophage in brain. It is a complex, multidomain protein that acts as a negative regulator downstream from TREM2.

View Article and Find Full Text PDF

Background: Positive findings from testing therapeutics in AD animal models are often not translated to effective treatments due to the poor methodological rigor and inadequate reporting practices of therapeutic efficacy studies. The Alzheimer's Disease Preclinical Efficacy Database (AlzPED), developed by the NIA, is a searchable and publicly available knowledgebase that prioritizes and promotes the use of rigorous methodology to ameliorate this translation gap. Through a checklist of experimental design elements - the Rigor Report Card - AlzPED highlights reporting recommendations and standards while providing a practical tool to help plan rigorous therapeutic studies in animals.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

School of Medicine, Johns Hopkins University, and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.

Background: Agitation is a common and disabling symptom of Alzheimer's dementia (AD). Pharmacological treatments are recommended if agitation is not responsive to psychosocial intervention. Citalopram was effective in treating agitation in AD but was associated with cognitive and cardiac risks linked to its R- but not S-enantiomer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!